Replay Launches Eudora to Target Genetic Retinal Diseases

Platform technology company Replay has launched Eudora, a gene therapy company targeting genetic diseases of the retina.

Eudora will utilize Replay’s high payload capacity herpes simplex virus (HSV) vector to deliver gene therapy payloads, the company announced Monday.